Aspheric-based procedures reduce need for re-treatments

Article

Aspheric-based treatments with the SCHWIND ESIRIS excimer laser and ORK-CAM software offer high predictability, increases in visual acuity (VA) and no induction of aberrations.

Aspheric-based treatments with the SCHWIND ESIRIS excimer laser and ORK-CAM software offer high predictability, increases in visual acuity (VA) and no induction of aberrations, according to a recent multicentre study conducted by Maria Clara Arbelaez, MD of the Muscat Eye Laser Center, Muscat, Oman and colleagues from the Charles University, Czech Republic.

The study of 183 eyes utilized the SCHWIND aberration-free treatment, which is designed to leave preoperative higher-order aberrations (HOAs) unchanged allowing patients to retain a habitual sight impression. All flaps were created using the Carriazo-Pendular microkeratome.

In 71% of eyes, the planned refractive result was achieved with a minimum deviation of ±0.25 D. Ninety-one percent were in the area of ±0.5 D and 100% of eyes achieved ±1 D.

Postoperative vision without aids compared with preoperative vision with glasses or contact lenses also increased significantly. At six-months follow-up, 86% of all eyes had achieved an uncorrected visual acuity (UCVA) of 20/20 or better, while only 69% had a best corrected visual acuity (BCVA) of 20/20 or better.

The study also demonstrated that the ORK-CAM software effectively aids the compensation of biomechanical changes of the cornea. At six-months follow-up, no growth of significant aberrations, such as coma or spherical aberration were observed.

It was concluded that the ESIRIS excimer laser and ORK-CAM software can provide good visual results as well as reducing the need for re-treatments.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Jay Chhablani, MD, shares late-breaking data from the ArMaDa trial, investigating gene therapy for Geographic Atrophy and dry age-related macular degeneration, at EURETINA
Editorial advisory board member Alexandra Miere, MD, PhD, speaks about the ACTOR and HERMES studies at the 2025 European Society of Retina Specialists (EURETINA) Congress
María Berrocal, MD, speaks about the Vit-Buckle Society symposium hosted at the 2025 European Society of Retina Specialists (EURETINA) annual meeting
© 2025 MJH Life Sciences

All rights reserved.